Nabriva Therapeutics Provides Business Update and Announces Preliminary Financial Results for the Fourth Quarter of 2021
January 10, 2022 07:00 ET
|
Nabriva Therapeutics US, Inc
-SIVEXTRO® (tedizolid phosphate) remains on track for return to historical peak sales by mid-2022- -XENLETA® (lefamulin) Phase I Cystic Fibrosis (CF) trial on track to enroll first patient in Q122- ...
Nabriva Therapeutics to Adjourn Extraordinary General Meeting of Shareholders on December 22, 2021
December 22, 2021 09:20 ET
|
Nabriva Therapeutics US, Inc
DUBLIN, Ireland and FORT WASHINGTON, Pa., Dec. 22, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development...
Nabriva Therapeutics to Present at the H.C. Wainwright BioConnect Virtual Conference
December 21, 2021 16:05 ET
|
Nabriva Therapeutics US, Inc
DUBLIN, Ireland and FORT WASHINGTON, Pa., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of...
Lefamulin NDA Filed in Mainland China for Treatment of Community Acquired Pneumonia
November 29, 2021 09:00 ET
|
Nabriva Therapeutics US, Inc
DUBLIN, Ireland and FORT WASHINGTON, Pa., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of...
Nabriva Announces Availability of XENLETA® (lefamulin) in a 10-Count Oral Pack
November 11, 2021 07:01 ET
|
Nabriva Therapeutics US, Inc
DUBLIN, Ireland and FORT WASHINGTON, Pa., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of...
Nabriva Therapeutics Reports Third Quarter 2021 Financial Results and Provides a Corporate Update
November 09, 2021 16:01 ET
|
Nabriva Therapeutics US, Inc
-Revenues of $8.9 million increased 8% sequentially versus Q2 2021- -SIVEXTRO Net Sales & Prescriptions both grew 14% sequentially versus Q2 2021- -Cash runway extended to substantially through...
Nabriva Therapeutics to Present at the Jefferies London Healthcare Conference
November 05, 2021 07:01 ET
|
Nabriva Therapeutics US, Inc
DUBLIN, Ireland and FORT WASHINGTON, Pa., Nov. 05, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of...
Nabriva Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
November 01, 2021 07:01 ET
|
Nabriva Therapeutics US, Inc
DUBLIN, Ireland, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective...
Nabriva Therapeutics to Report Third Quarter 2021 Financial Results and Recent Corporate Highlights on November 9, 2021
October 26, 2021 07:01 ET
|
Nabriva Therapeutics US, Inc
DUBLIN, Ireland, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective...
Nabriva Therapeutics to Present Data at CHEST Annual Meeting 2021
October 15, 2021 16:05 ET
|
Nabriva Therapeutics US, Inc
DUBLIN, Ireland and FORT WASHINGTON, Pa., Oct. 15, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of...